Enrollment complete in relacorilant Phase 3 GRADIENT trial
A Phase 3 trial testing the oral medication relacorilant in people with Cushing’s syndrome caused by adrenal adenoma, a type of adrenal gland tumor, or adrenal hyperplasia, a condition in which the adrenal glands become enlarged, has finished enrolling participants. Relacorilant’s developer, Corcept Therapeutics, said 137 participants have…